Viamet Pharma Signs Option Deal with Novartis
Viamet Pharmaceuticals Inc., a Morrisville, N.C.-based biotech company targeting metalloenzymes, has signed a licensing option agreement with Novartis Option Fund. The deal could be worth upwards of $200 million, including an up-front payment and earnouts. Viamet previously raised around $24 million in VC funding, from Novartis Option Fund, Lilly Ventures, Intersouth Partners, Hatteras Venture Partners, Lurie Investment Fund and Astellas Venture Management.
22 February 2010•3 mins read
